Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

Xiaosheng Wu, Mary Stenson, Jithma Abeykoon, Kevin Nowakowski, Lianwen Zhang, Joshua Lawson, Linda Wellik, Ying Li, Jordan Krull, Kerstin Wenzl, Anne J. Novak, Stephen M. Ansell, Gail A. Bishop, Daniel D. Billadeau, Kah Whye Peng, Francis Giles, Daniel M. Schmitt, Thomas E. Witzig

Blood (2019) 134 (4): 363–373.

https://doi.org/10.1182/blood.2018874560

Published: 2019

Includes: Supplemental data

Journal Articles

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Thomas E. Witzig, Craig Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Mamta Gupta

Blood (2015) 126 (3): 328–335.

https://doi.org/10.1182/blood-2015-02-629543

Published: 2015

Includes: Supplemental data

Journal Articles

Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma

Mohamad Bassam, M.D, Matthew J Maurer, MS, Mary Stenson, B.S, Linda E Wellik, Christine Allmer, Brian K Link, MD, James R Cerhan, MD, PhD, Thomas E Witzig, MD, Mamta Gupta, Ph.D

Blood (2013) 122 (21): 4256.

https://doi.org/10.1182/blood.V122.21.4256.4256

Published: 2013

Journal Articles

SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark

Mamta Gupta, Ph.D, Guangzhen Hu, Linda E Wellik, Jing Jing Han, Mary Stenson, B.S, Ahmet Dogan, MD, PhD, Thomas E Witzig, MD

Blood (2013) 122 (21): 632.

https://doi.org/10.1182/blood.V122.21.632.632

Published: 2013

Journal Articles

Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells

Mamta Gupta, Ph.D, Jing Jing Han, Mary Stenson, B.S, Linda E Wellik, Thomas E Witzig, MD

Blood (2013) 122 (21): 636.

https://doi.org/10.1182/blood.V122.21.636.636

Published: 2013

Journal Articles

In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy

Mamta Gupta, Ph.D, Matthew J. Maurer, MS, Mary Stenson, B.S, Linda E. Wellik, Jing Jing Han, Andrew L. Feldman, Thomas M. Habermann, MD, Thomas E. Witzig, MD

Blood (2013) 122 (21): 844.

https://doi.org/10.1182/blood.V122.21.844.844

Published: 2013

Journal Articles

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Mamta Gupta, Jing Jing Han, Mary Stenson, Matthew Maurer, Linda Wellik, Guangzhen Hu, Steve Ziesmer, Ahmet Dogan, Thomas E. Witzig

Blood (2012) 119 (12): 2844–2853.

https://doi.org/10.1182/blood-2011-10-388538

Published: 2012

Includes: Supplemental data

Journal Articles

Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation

Mamta Gupta, Ph.D, Mary Stenson, Jing Jing Han, Matthew J Maurer, MS, Linda Wellik, Steven C. Ziesmer, Ahmet Dogan, Thomas E. Witzig, MD

Blood (2011) 118 (21): 960.

https://doi.org/10.1182/blood.V118.21.960.960

Published: 2011

Journal Articles

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKT S473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

Mamta Gupta, Ph.D, Andrea Wahner Hendrickson, Jing Jing Han, Mary Stenson, Linda Wellik, Sharon Barr, Scott H. Kaufmann, MD, PhD, Thomas E. Witzig, MD

Blood (2010) 116 (21): 772.

https://doi.org/10.1182/blood.V116.21.772.772

Published: 2010

Journal Articles

HDAC Class I Inhibition Acetylates a Non-Histone Protein STAT3 by Modulating p300-STAT3-HDAC1 Interaction In Activated B- Cell Like (ABC) Diffuse Large B Cell Lymphoma

Mamta Gupta, Ph.D, Jing Jing Han, Mary Stenson, Linda Wellik, Thomas E. Witzig, MD

Blood (2010) 116 (21): 115.

https://doi.org/10.1182/blood.V116.21.115.115

Published: 2010

Journal Articles

Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.

Mamta Gupta, Mary Stenson, Terra Lasho, Ayalew Tefferi, Anne Novak, Stephen M. Ansell, Thomas E. Witzig

Blood (2009) 114 (22): 925.

https://doi.org/10.1182/blood.V114.22.925.925

Published: 2009

Journal Articles

The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.

Tait D. Shanafelt, MD, Yean K. Lee, Susan M. Geyer, PhD, Deanna Grote, Mary Stenson, Steven Zincke, Stephen M. Ansell, MD/PhD, Thomas E. Witzig, MD, Neil E. Kay, MD

Blood (2006) 108 (11): 234.

https://doi.org/10.1182/blood.V108.11.234.234

Published: 2006

Journal Articles

Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.

Laila K. Ismail, MD, Michael Timm, BS, Anne Novak, PhD, Mary Stenson, BS, Stephen M. Ansell, MD, PhD, Thomas E. Witzig, MD

Blood (2005) 106 (11): 2411.

https://doi.org/10.1182/blood.V106.11.2411.2411

Published: 2005

Journal Articles

Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome

Anne J. Novak, Deanna M. Grote, Mary Stenson, Steven C. Ziesmer, Thomas E. Witzig, Thomas M. Habermann, Brandon Harder, Kay M. Ristow, Richard J. Bram, Diane F. Jelinek, Jane A. Gross, Stephen M. Ansell

Blood (2004) 104 (8): 2247–2253.

https://doi.org/10.1182/blood-2004-02-0762

Published: 2004

NARROW

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma

SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark

Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells

In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKT S473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

HDAC Class I Inhibition Acetylates a Non-Histone Protein STAT3 by Modulating p300-STAT3-HDAC1 Interaction In Activated B- Cell Like (ABC) Diffuse Large B Cell Lymphoma

Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.

The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.

Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.

Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only